HE4 in endometriod and non- endometrioid subtype of endometrial cancer does not mean the same

Objective: To study the association between the preoperative value of serum HE4 marker and poor histological prognostic factors depending on the subtype of endometrial cancer (EC): endometrioid and non-endometrioid tumors. Methods: Prospective and multicenter cohort study including patients with EC in Miguel Servet University Hospital of Zaragoza (Spain) and Hospital Clínico San Carlos of Madrid (Spain) from January 2017 to March 2020. Preoperative serum levels of HE4 were analyzed by clinical and pathological characteristics. Results: Overall, 190 patients were included. Of them, 158 were subtype I of EC and 32 were subtype II tumors. In endometrioid EC, a statistically significant association was found between the preoperative HE4 value and tumor size (p < 0.001), deep myometrial invasion (p = 0.001), lymphovascular space invasion (LVSI) (p = 0.002), cervical (p = 0.001), adnexal (p = 0.023), isthmus (p < 0.001) and parametrial involvement (p = 0.012), lymph node metastasis (p = 0.025) and FIGO stage (p < 0.001). On the contrary, no histological factors showed statistical association except LVSI (p = 0.025) in the non-endometrioid subtype. Conclusions: The preoperative value of HE4 is related differently with several established prognostic factors for EC according to the histological type of tumor. These results could be relevant in order to standardize a prognostic value of HE4 in EC.

HE4; Endometrioid endometrial cancer; Serous endometrial cancer; Clear cells endometrial cancer.

[1] Endometrial Cancer. NCI cancer statistics. Available at: http://www. cancer.gov/types/uterine.

[2] Felix A.S., Yang H.P., Bell D.W., Sherman M.E.: “Epidemiology of endometrial carcinoma: etiologic importance of hormonal and metabolic influences”. Adv. Exp. Med. Biol., 2017, 294, 3-46.

[3] Baquedano L., Castán S., Ruiz-Conde M.A., Martinez-Maestre M. A., Judez D., Coronado P.J.: “Prognostic factors in high-grade endometrial cancer: does subtype matter?” Eur. J. Gynaecol. On-col., 2019, 40, 254-261.

[4] Lee Y., Kim Y., Kang J., Nam S., Kim D., Kim Y.: “Comparison of risk of ovarian malignancy algorithm and cancer antigen 125 to discriminate between benign ovarian tumor and early-stage ovarian cancer according to imaging tumor subtypes”. Oncol. Lett., 2020, 20, 931-938.

[5] Espiau Romera A., Cuesta Guardiola T., Benito Vielba M., De Bonrostro Torralba C., Coronado Martín P.J., Baquedano Mainar L.: “HE4 tumor marker as a predictive factor for lymphatic metastasis in endometrial cancer”. Int. J. Gynaecol. Obstet., 2020, 149, 265-268.

[6] Oncoguía SEGO. Cáncer de Endometrio 2016. Guías de práctica clínica en cáncer ginecológico y mamario. Publicaciones: SEGO, Febrero. 2016. (In Spanish)

[7] Colombo N., Creutzberg C., Amant F., Bosse T., González-Martín A., Ledermann J., et al.: “ESMO-ESGO-ESTRO consensus conference on endometrial cancer”. Int. J. Gynecol. Cancer, 2016, 26, 2- 30.

[8] Kurman R.J., Carcangiu M.L., Herrington C.S., Young R.H. WHO classification of tumours of female reproductive organs. WHO classification of tumours. 4th Edition, Volume 6. Lyon: International Agency for Research on Cancer. 2014.

[9] Bokhman J.V.: “Two pathogenetic types of endometrial carcinoma”. Gynecol. Oncol., 1983, 15, 10-17.

[10] Ayeni T.A., Bakkum-Gamez J.N., Mariani A., McGree M.E., Weaver A.L., Haddock M.G., et al.: “Comparative outcomes assessment of uterine grade 3 endometrioid, serous, and clear cell carcinomas”. Gynecol. Oncol., 2013, 129, 478-485.

[11] Simmons A.R., Baggerly K., Bast R.C.: “The emerging role of HE4 in the evaluation of epithelial ovarian and endometrial carcinomas”. Oncology (Williston Park, N.Y.), 2013, 27, 548-556.

[12] Lu R., Sun X., Xiao R., Zhou L., Gao X., Guo L.: “Human epi-didymis protein 4 (HE4) plays a key role in ovarian cancer cell adhesion and motility”. Biochem. Biophys. Res. Commun., 2012, 419, 274- 280.

[13] Moore R.G., McMeekin D.S., Brown A.K., DiSilvestro P., Miller M. C., Allard W.J., et al.: “A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass”. Gynecol. Oncol., 2009, 112, 40-46.

[14] Bignotti E., Ragnoli M., Zanotti L., Calza S., Falchetti M., Lonardi S., et al.: “Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patients”. Br. J. Cancer, 2011, 104, 1418-1425.

[15] Zanotti L., Bignotti E., Calza S., Bandiera E., Ruggeri G., Galli C., et al.: “Human epididymis protein 4 as a serum marker for diagnosis of endometrial carcinoma and prediction of clinical outcome”. Clin. Chem. Lab. Med., 2012, 50, 2189-2198.

[16] Wang Y., Han C., Teng F., Bai Z., Tian W., Xue F.: “Predictive value of serum HE4 and CA125 concentrations for lymphatic metastasis of endometrial cancer”. Int. J. Gynaecol. Obstet., 2017, 136, 58-63.

[17] Moore R.G., Brown A.K., Miller M.C., Badgwell D., Lu Z., Allard W. J., et al.: “Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus”. Gynecol. Oncol., 2008, 110, 196-201.

[18] Moore R.G., Miller C.M., Brown A.K., Robison K., Steinhoff M., Lambert-Messerlian G.: “Utility of tumor marker HE4 to predict depth of myometrial invasion in endometrioid adenocarcinoma of the uterus”. Int. J. Gynecol. Cancer, 2011, 21, 1185-1190.

[19] Kalogera E., Scholler N., Powless C., Weaver A., Drapkin R., Li J., et al.: “Correlation of serum HE4 with tumor size and myometrial invasion in endometrial cancer”. Gynecol. Oncol., 2012, 124, 270-275.

[20] Bie Y., Zhang Z.: “Diagnostic value of serum HE4 in endometrial cancer: a meta-analysis”. World J. Surg. Oncol., 2014, 12, 169.

[21] Mutz-Dehbalaie I., Egle D., Fessler S., Hubalek M., Fiegl H., Marth C., et al.: “HE4 is an independent prognostic marker in endometrial cancer patients”. Gynecol. Oncol., 2012, 126, 186-191.

[22] Saarelainen S.K., Peltonen N., Lehtimäki T., Perheentupa A., Vuento M.H., Mäenpää J.U.: “Predictive value of serum human epididymis protein 4 and cancer antigen 125 concentrations in endome-trial carcinoma”. Am. J. Obstet. Gynecol., 2013, 209, 142.e1-142.e6.

[23] Li Y., Cong P., Wang P., Peng C., Liu M., Sun G.: “Risk factors for pelvic lymph node metastasis in endometrial cancer”. Arch. Gynecol. Obstet., 2019, 300, 1007-1013.

[24] Bosse T., Peters E.E.M., Creutzberg C.L., Jürgenliemk-Schulz I.M., Jobsen J.J., Mens J.W.M., et al.: “Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endome-trial cancer - A pooled analysis of PORTEC 1 and 2 trials”. Eur. J. Cancer, 2015, 51, 1742-1750.

[25] Colombo N., Creutzberg C., Amant F., Bosse T., González-Martín A., Ledermann J., et al.: “ESMO-ESGO-ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up”. Radiother. Oncol., 2015, 117, 559-581.

[26] Abbink K., Zusterzeel P.L., Geurts-Moespot A.J., Herwaarden A.E.V., Pijnenborg J.M., Sweep F.C., et al.: “HE4 is superior to CA125 in the detection of recurrent disease in high-risk endometrial cancer patients”. Tumour Biol., 2018, 40, 1010428318757103.

[27] Stiekema A., Lok C., Korse C., van Driel W., van der Noort V., Kenter G., et al.: “Serum HE4 is correlated to prognostic factors and survival in patients with endometrial cancer”. Virchows Arch., 2017, 470, 655-664.

[28] Dai C., Zheng Y., Li Y., Tian T., Wang M., Xu P., et al.: “Prognostic values of HE4 expression in patients with cancer: a meta-analysis”. Cancer Manag Res., 2018, 10, 4491-4500.

[29] Li J., Wang X., Qu W., Wang J., Jiang S.: “Comparison of serum human epididymis protein 4 and CA125 on endometrial cancer detection: a meta-analysis”. Clin. Chim. Acta, 2019, 488, 215-220.